

Rectal Cancer Multidisciplinary Conference - 7/31/2025
7/31/2025 4:30:00 PM - 7/31/2025 5:30:00 PM

By texting in your attendance, you will be awarded the maximum number of CE credits. If you wish to claim less than the maximum CE credits, please contact MDAnderson-CPE@mdanderson.org

Target Audience:

Professions: Physician (MD or DO), Student or Trainee

Learning Objectives:

- 1 Identify and utilize the appropriate and optimal diagnostic modalities in solid tumor patients to improve patient outcomes
- 2 Describe the clinical and pathologic staging systems in solid tumors
- 3 Manage solid tumor patients by better identification of the role and timing of surgery, chemotherapy, and radiation therapy; thus, improving patient outcomes

Accreditation:



In support of improving patient care, The University of Texas MD Anderson Cancer Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Credit Designation:

The University of Texas MD Anderson Cancer Center designates this live activity for a maximum of 1.00 *AMA PRA Category 1 Credits*[™]. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

American Board of Surgery CC Credit:

Successful completion of this CME activity, enables the learner to earn credit toward the CME of the American Board of Surgery's Continuous Certification program. It is the CME activity provider's responsibility to submit learner completion information to ACCME for purpose of granting ABS credit.

Commercial Support:

No commercial support has been received for this activity.

Disclosure of Financial Relationships:

The University of Texas MD Anderson Cancer Center adheres to the ACCME's Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty,

planners, reviewers or others are required to disclose all financial relationships with ineligible companies (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Faculty & Planner Disclosure:

Name of individual	Individual's role in activity	Nature of Relationship(s) / Name of Ineligible Company(s)
Brian K. Bednarski, MD	Activity Co-Director, Faculty	Nothing to disclose - 01/07/2025
George J. Chang, MD	Other Planning Committee Member	Consulting Fee-Medicaroid Consulting Fee-Iota Biosciences - 09/25/2024
Harmeet Kaur, MD	Activity Co-Director	Stocks or stock options, excluding diversified mutual funds-Nuance and Health Catalyst - 10/10/2024
Craig A. Messick, MD	Other Planning Committee Member	Nothing to disclose - 06/05/2025
Yi Qian You, MD	Other Planning Committee Member	Nothing to disclose - 06/16/2025
Tsuyoshi Konishi, MD	Other Planning Committee Member	Honoraria-Medtronic, Inc. (any division) (Relationship has ended) - 09/27/2024
Ramy Behman, MD	Faculty, Other Planning Committee Member	Nothing to disclose - 09/27/2024